Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05163041 · ClinicalTrials.gov registry record · Phase 1
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
A Phase 1 study of Advanced Solid Tumor, sponsored by BicycleTx Limited.
- Active
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
- 9
- Study locations
NCT05163041: Active Phase 1 study of Advanced Solid Tumor, sponsored by BicycleTx Limited.
NCT05163041 is a Phase 1 study of Advanced Solid Tumor that is active but no longer recruiting, run by BicycleTx Limited. The registered enrollment target is 200 participants, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target. The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05163041, a Phase 1 study of Advanced Solid Tumor, is active but no longer recruiting, sponsored by BicycleTx Limited.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
- 9
- Study locations
Study Summary
This clinical study is evaluating a drug called BT7480 alone and in combination with nivolumab in participants with advanced solid tumors associated with Nectin-4 expression. The main goals of the study are to: * Find the recommended dose of BT7480 that can be given safely to participants alone and in combination with nivolumab * Learn about the side effects and effectiveness of BT7480 alone and in combination with nivolumab * Learn about the effect BT7480 has on the body and how BT7480 is cleared by the body * Learn about the side effects and effectiveness of BT7480 in patients with reduced kidney function
Primary Outcome
Incidence and severity of treatment emergent adverse events to assess safety and tolerability following treatment with BT7480 alone and in patients with renal insufficiency using NCI CTCAE v5.0 criteria
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG BT7480
Study Locations (9)
Texas
- MD Anderson Cancer Center - Houston
- START Center for Cancer Care - San Antonio
Iowa
- State University of Iowa - Iowa City
New York
- Columbia University Irving Medical Center - New York
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Virginia
- Virginia Cancer Specialists - Fairfax
Surrey
- The Royal Marsden NHS Foundation Trust - Sutton
Other
- The Beatson West of Scotland Cancer Centre - Glasgow
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2021-11-02 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What the registry record for NCT05163041 still lists
NCT05163041 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target.
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT05163041 lists 9 locations in 8 states (Texas, Iowa, New York).
Frequently Asked Questions
What is clinical trial NCT05163041 about?
NCT05163041 is a clinical study titled "Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression". This clinical study is evaluating a drug called BT7480 alone and in combination with nivolumab in participants with advanced solid tumors associated with Nectin-4 expression. The main goals of the study are to: * Find the recommended dose of BT7480 that can be given safely to participants alone an...
What is the current status of trial NCT05163041?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2021-11-02. Estimated completion is 2026-12.
What conditions does trial NCT05163041 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT05163041?
The interventions under investigation include: Nivolumab (DRUG), BT7480 (DRUG).
Who is sponsoring clinical trial NCT05163041?
This trial is sponsored by BicycleTx Limited, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05163041 being conducted?
This trial has 9 study locations across Iowa, New York, Ohio, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05163041's enrollment target sits among peer trials
200 66th of 189 higher than 121 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI